You're asking about **1-[3-[(5-bromo-2-pyridinyl)-(phenylmethyl)amino]propyl]-3-[3-(1H-imidazol-5-yl)propyl]thiourea**. This is a complex organic molecule with a long, descriptive name, but it's important to understand the key parts and their potential significance:
**Breaking Down the Name:**
* **1-[3-[(5-bromo-2-pyridinyl)-(phenylmethyl)amino]propyl]-3-[3-(1H-imidazol-5-yl)propyl]thiourea:**
* **Thiourea:** This is the core structure of the molecule, a functional group with a sulfur atom linked to a nitrogen atom. Thioureas are known for their biological activity and are found in various drugs.
* **(5-bromo-2-pyridinyl)-(phenylmethyl)amino:** This portion of the molecule contains a substituted pyridine ring (a 6-membered ring with nitrogen) with a bromine atom and a phenylmethyl (benzyl) group attached to an amino group.
* **[3-(1H-imidazol-5-yl)propyl]:** This part contains an imidazole ring (a 5-membered ring with two nitrogen atoms) linked to a propyl chain.
**Potential Research Importance:**
The complex structure suggests this molecule might have several potential applications in research:
* **Pharmacological Activity:** The combination of a thiourea core with a pyridine, benzyl, and imidazole moieties could lead to interactions with biological targets, such as enzymes or receptors. This could make it useful for:
* **Drug discovery:** It might be a lead compound for developing new drugs.
* **Biological probes:** It could be used to study specific biological processes by binding to target molecules.
* **Materials Science:** The molecule's structure might offer properties useful in materials science, such as:
* **Polymerization:** Thiourea derivatives can be used to create polymers with interesting properties.
* **Self-assembly:** The molecule's distinct functional groups could lead to self-assembly into ordered structures.
* **Organic Synthesis:** The molecule's synthesis itself could be of interest to researchers studying:
* **New reaction pathways:** The molecule's synthesis might require new or optimized synthetic methods.
* **Functional group chemistry:** The synthesis might showcase new reactions or modifications involving thioureas, pyridines, or other functional groups.
**Important Note:**
Without more context about the research being done, it's difficult to say definitively why this specific molecule is important. You'll need to look for the source of this information to find out the specific research context and what the researchers are trying to achieve.
ID Source | ID |
---|---|
PubMed CID | 44820554 |
CHEMBL ID | 1314160 |
CHEBI ID | 92581 |
Synonym |
---|
NCGC00185839-01 |
smr001566923 |
MLS002703118 |
CHEMBL1314160 |
CHEBI:92581 |
Q27164302 |
1-[3-[(5-bromo-2-pyridinyl)-(phenylmethyl)amino]propyl]-3-[3-(1h-imidazol-5-yl)propyl]thiourea |
Class | Description |
---|---|
aminopyridine | Compounds containing a pyridine skeleton substituted by one or more amine groups. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 56.2341 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
Smad3 | Homo sapiens (human) | Potency | 31.6228 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
glucocerebrosidase | Homo sapiens (human) | Potency | 5.7935 | 0.0126 | 8.1569 | 44.6684 | AID2590 |
DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 22.3872 | 0.0580 | 10.6949 | 26.6086 | AID602310 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID1119120 | Inhibition of glucocerebrosidase N370S mutant in spleen homogenates of patient with Gaucher disease using resorufin-beta-D-glucopyranoside as substrate after 20 mins fluorescence assay | 2012 | MedChemComm, Jan, Volume: 3, Issue:1 | Non-iminosugar glucocerebrosidase small molecule chaperones. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |